Abvc BiopharmaABVC
13F holders, Q3 2024 (September 30)9holders −2
1new positions
2sold out
$0.68avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, down 2 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($49K), Vanguard Group Inc. ($32K) and Avantax Planning Partners, Inc. ($27K).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8K |
| Exits | 2 | $20K |
All 13F filers, Q2 2024 → Q3 2024: 33,240 shares bought and 25,450 shares sold, net +7,790 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Geode Capital Management, LLC | 0.00% | Add +29.7% | 71,607 | $49K |
| Vanguard Group Inc. | 0.00% | No change | 46,947 | $32K |
| Avantax Planning Partners, Inc. | 0.00% | No change | 39,000 | $27K |
| XTX Topco Ltd | 0.00% | Add +23.6% | 23,405 | $16K |
| Northern Trust Corp. | 0.00% | No change | 19,135 | $13K |
| State Street Corp. | 0.00% | No change | 12,900 | $9K |
| Two Sigma Securities, LLC | 0.00% | New | 12,397 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.9% | 2,623 | $2K |
| Bank of America Corp. | 0.00% | Reduce -69.5% | 78 | $53 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.